反応式
[NH2:1][C:2]1[CH:31]=[CH:30][C:5]([O:6][C:7]2[CH:12]=[CH:11][N:10]=[C:9]3[CH:13]=[C:14]([C:16]4[CH:21]=[CH:20][C:19]([C:22]([N:24]5[CH2:29][CH2:28][O:27][CH2:26][CH2:25]5)=[O:23])=[CH:18][CH:17]=4)[S:15][C:8]=23)=[C:4]([F:32])[CH:3]=1.[NH:33]1[C:37]2[CH:38]=[CH:39][CH:40]=[CH:41][C:36]=2[N:35]=[C:34]1[CH2:42][C:43](O)=[O:44]>>[NH:33]1[C:37]2[CH:38]=[CH:39][CH:40]=[CH:41][C:36]=2[N:35]=[C:34]1[CH2:42][C:43]([NH:1][C:2]1[CH:31]=[CH:30][C:5]([O:6][C:7]2[CH:12]=[CH:11][N:10]=[C:9]3[CH:13]=[C:14]([C:16]4[CH:17]=[CH:18][C:19]([C:22]([N:24]5[CH2:25][CH2:26][O:27][CH2:28][CH2:29]5)=[O:23])=[CH:20][CH:21]=4)[S:15][C:8]=23)=[C:4]([F:32])[CH:3]=1)=[O:44]参加物
3
実験手順
Prepared from (4-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)phenyl)(morpholino)methanone (Example 129, Step A) and 2-(1H-benzo[d]imidazol-2-yl)acetic acid according to the procedure of Example 89. The crude was purified by preparative HPLC to afford the desired product (1.9 mg, 6%). LRMS (ESI pos) m/e 607.9 (M+1). 1H-NMR (400 MHz, CD3OD) δ 8.53 (d, 1H), 7.94 (m, 4H), 7.81 (m, 2H), 7.61 (m, 4H), 7.47 (m, 2H), 6.74 (d, 1H), 3.73 (m, 8H), 3.50 (m, 2H); 19F NMR (376 MHz, CD3OD) δ −129.6.
後処理
- customThe crude was purified by preparative HPLC
出典と根拠
- ORDレコード
- ord-2a21113bc3cc4e44aec64cb4eaaece3c
- 出典データセット
- uspto-grants-2011_08
- 特許番号
- US08003662B2
関連ノート
読み込み中…